CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 8 enrolled
Drug / intervention
Dexlansoprazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02096458
NCT02096458Phase 1Completed
CompareCT.gov

An Open-Label Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Subjects : TAK-390MR(OD)_107

Takeda·interventional·Posted Mar 26, 2014·Updated Mar 6, 2015

In Brief

A Phase 1 clinical trial evaluating Dexlansoprazole for Gastroesophageal Reflux Disease and 2 related conditions. Completed, enrolled 8 participants across 1 site.

Detailed Summary

The purpose of this study is to measure the in-vivo disintegration time of a single dexlansoprazole delayed-release orally disintegrating (OD) tablet.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 26, 2014
Enrollment StartFeb 1, 2014
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 12.3 years ago

Interventions

Dexlansoprazoledrug

Dexlansoprazole delayed-release orally disintegrating tablets